Patents by Inventor Paul L. Skatrud
Paul L. Skatrud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6322998Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.Type: GrantFiled: October 29, 1992Date of Patent: November 27, 2001Assignee: Eli Lilly and CompanyInventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
-
Patent number: 6180361Abstract: The present invention provides DNA compounds that encode the expandase/hydroxylase enzyme of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a variety of host cells, including E. coli, Penicillium, and Cephalosporium.Type: GrantFiled: December 12, 1988Date of Patent: January 30, 2001Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud
-
Patent number: 6143868Abstract: The invention provides isolated nucleic acid compounds encoding a novel MTG of Staphylococcus aureus. Also provided are vectors and transformed heterologous host cells for expressing the MTG and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the MTG.Type: GrantFiled: April 9, 1998Date of Patent: November 7, 2000Assignee: Eli Lilly and CompanyInventors: Jo Ann Hoskins, Stanley R. Jaskunas, Jr., Robert B. Peery, Paul L. Skatrud
-
Patent number: 5922540Abstract: The invention provides isolated nucleic acid compounds encoding a novel MTG of Staphylococcus aureus. Also provided are vectors and transformed heterologous host cells for expressing the MTG and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the MTG.Type: GrantFiled: December 20, 1996Date of Patent: July 13, 1999Assignee: Eli Lilly and CompanyInventors: Jo Ann Hoskins, Stanley R. Jaskunas, Jr., Robert B. Peery, Paul L. Skatrud
-
Patent number: 5919617Abstract: The present invention provides novel methods and materials for detecting the presence of a fungus in a biological sample. The inventive methods and materials exploit the fact that the amino acid sequence of the saccharopine dehydrogenase molecule is highly conserved in fungi. Inventive hybridization probes, nucleic acids, PCR primers, antibodies, epitopes, reagents and methods are provided.Type: GrantFiled: December 21, 1994Date of Patent: July 6, 1999Assignee: Miami UniversityInventors: Jnanendra K. Bhattacharjee, Richard C. Garrad, Paul L. Skatrud, Robert B. Peery
-
Patent number: 5776695Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.Type: GrantFiled: April 15, 1997Date of Patent: July 7, 1998Assignee: Eli Lilly and CompanyInventors: Paul L. Skatrud, Robert B. Peery
-
Patent number: 5776733Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.Type: GrantFiled: July 25, 1996Date of Patent: July 7, 1998Assignee: Eli Lilly and CompanyInventors: Paul L. Skatrud, Robert B. Peery
-
Patent number: 5773214Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus flavus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus flavus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.Type: GrantFiled: February 27, 1995Date of Patent: June 30, 1998Assignee: Eli Lilly and CompanyInventors: Robert B. Peery, Paul L. Skatrud
-
Patent number: 5770415Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.Type: GrantFiled: March 17, 1997Date of Patent: June 23, 1998Assignee: Eli Lilly and CompanyInventors: Paul L. Skatrud, Robert B. Peery
-
Patent number: 5710018Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.Type: GrantFiled: June 5, 1995Date of Patent: January 20, 1998Assignee: Eli Lilly and CompanyInventors: Anne H. Dantzig, Jo Ann Hoskins, Paul L. Skatrud
-
Patent number: 5705352Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus fumigatus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus fumigatus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.Type: GrantFiled: February 27, 1995Date of Patent: January 6, 1998Assignee: Eli Lilly and CompanyInventors: Robert B. Peery, Paul L. Skatrud
-
Patent number: 5691161Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.Type: GrantFiled: August 1, 1996Date of Patent: November 25, 1997Assignee: Eli Lilly and CompanyInventors: Paul L. Skatrud, Robert B. Peery
-
Patent number: 5620855Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.Type: GrantFiled: May 1, 1995Date of Patent: April 15, 1997Assignee: Eli Lilly and CompanyInventors: Anne H. Dantzig, Jo A. Hoskins, Paul L. Skatrud
-
Patent number: 5587307Abstract: The instant invention provides the femA gene of Staphylococcus epidermidis and all degenerate sequences thereof, the protein encoded by the femA gene (FemA), and vectors and microorganisms comprising genes encoding the FemA protein.Type: GrantFiled: October 27, 1994Date of Patent: December 24, 1996Assignee: Eli Lilly and CompanyInventors: William E. Alborn, Jr., JoAnn Hoskins, Paul L. Skatrud, Serhat Unal
-
Patent number: 5516655Abstract: The invention provides isolated nucleic acid compounds encoding the multiple drug resistance protein of Aureobasidium pullulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aureobasidium pullulans are also provided. The invention further provides assays which utilize these transformed host cells.Type: GrantFiled: April 20, 1994Date of Patent: May 14, 1996Assignee: Eli Lilly and CompanyInventors: Robert B. Peery, Paul L. Skatrud
-
Recombinant DNA expression vectors and DNA compounds that encode deacetoxycephalosporin C synthetase
Patent number: 5070020Abstract: The present invention provides DNA compounds that encode deacetoxycephalosporin C synthetase (DAOCS) activity. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Streptomyces, Aspergillus, and Cephalosporium.Type: GrantFiled: May 9, 1988Date of Patent: December 3, 1991Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Steven Kovacevic, James R. Miller, Paul L. Skatrud -
Patent number: 4892819Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase. The invention also comprises methods, transformants, and polypeptides related to the novel DNA compounds. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcription and translation activating sequence, was isolated from Penicillium chrysogenum. The isopenicillin N synthetase-encoding DNA can be used to construct novel E. coli expression vectors that drive expression of isopenicillin N synthetase in E. coli. The intact P. chrysogenum isopenicillin N synthetase-encoding DNA and associated transcription and translation activating sequence can also be used to construct expression vectors that drive expression of the isopenicillin N synthetase in P. chrysogenum and Cephalosporium acremonium. The transcription and translation activating sequence can be fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto expression vectors that function in P. chrysogenum and C.Type: GrantFiled: November 25, 1985Date of Patent: January 9, 1990Assignee: Eli Lilly and CompanyInventors: Lucinda G. Carr, Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud
-
Patent number: 4885251Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase and also comprises related methods, transformants, and polypeptides. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcriptional and translational activating sequence, was isolated from Cephalosporium acremonium and cloned into an E. coli cloning vector. The isopenicillin N synthetase-encoding DNA has been used to construct novel E. coli expression vectors that drive expression of a stable, active, and novel isopenicillin N synthetase in E. coli. The intact C. acremonium isopenicillin N synthetase-encoding DNA and associated transcriptional and translational activating sequence have also been used to construct C. acremonium expression vectors that drive expression of the isopenicillin N synthetase in C. acremonium. The C. acremonium transcriptional and translational activating sequence has further been fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto C.Type: GrantFiled: August 8, 1986Date of Patent: December 5, 1989Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud, Otis W. Godfrey
-
Patent number: 4885252Abstract: DNA compounds and recombinant DNA expression vectors that encode and drive expression in recombinant host cells of the isopenicillin N synthetase activity of Aspergillus nidulans are useful to produce isopenicillin N synthetase and to improve the yield of .beta.-lactam-containing antibiotics from antibiotic-producing organisms. The isopenicillin N synthetase gene of A. nidulans can be isolated from plasmid pOGOO4, available from the Northern Regional Research Center under the accession number NRRL B-18171.Type: GrantFiled: December 14, 1987Date of Patent: December 5, 1989Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud, Barbara J. Wiegel
-
Patent number: 4762786Abstract: A method for transforming Cephalosporium and other lower eukaryotes is disclosed. The method involves inserting a recombinant DNA cloning vector comprising a Saccharomyces cerevisiae transcriptional and translational activating sequence positioned for expression of hygromycin phosphotransferase into a host cell and then growing the host cell under selective conditions. The vectors optionally further comprise Cephalosporium ribosomal DNA and also sequences that allow for replication and selection in E. coli and Streptomyces.Type: GrantFiled: September 27, 1984Date of Patent: August 9, 1988Assignee: Eli Lilly and CompanyInventors: Jerry L. Chapman, Jr., Thomas D. Ingolia, Kevin R. Kaster, Stephen W. Queener, Paul L. Skatrud